The Battle Against Systemic Sclerosis: A Case Report of a Patient With Scleroderma Renal Crisis.
- 1Department of Nephrology, Hypertension, Transplantation, and Internal Medicine, Medical University of Lodz, Lodz, POL.
- 2Department of Dermatology, Dammam Health Network, Dammam, SAU.
Abstract
Systemic scleroderma (SSc) is an uncommon autoimmune disorder that causes excessive fibrosis of the skin and internal organs, especially the lungs, kidneys, and heart. Scleroderma renal crisis (SRC) is a rare and potentially fatal complication of SSc. In recent years, there has been an increasing interest in SSc treatment, but so far, the targeted management approach has been lacking. We report a 44-year-old male patient with overlap syndrome (systemic scleroderma, Sjogren's syndrome, and myositis), who underwent treatment with therapeutic plasma exchange (TPE) and received hemodialysis, angiotensin-converting enzyme inhibitors, glucocorticosteroids, and cyclophosphamide. The patient presented prominent cutaneous scleroderma with sclerodactyly and Raynaud's phenomenon. Despite the initial stabilization of the patient's condition on the multimodal pharmacotherapy combined with TPE, he later died from multi-organ failure. Although TPE performed during the early course of the disease has been reported as a potential adjunctive therapy, its efficacy and long-term benefits remain uncertain. Given the complexity of our patient's presentation, including scleroderma overlap syndrome and advanced, irreversible organ damage, it is difficult to determine whether TPE provided a meaningful clinical benefit.
Related
- Health literacy among people with systemic sclerosis: a Scleroderma Patient-Centred Intervention Network (SPIN) Cohort cross-sectional study
- Scleroderma Renal Crisis-Associated Thrombotic Microangiopathy Preceding Skin Sclerosis in Diffuse Cutaneous Systemic Sclerosis: A Case Report
- Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study
- Persistent Bacillus cereus bacteremia in a patient with systemic sclerosis-associated intestinal pseudo-obstruction: A case report.
- Twenty years in the battle against sudden cardiac death: progress, pitfalls, and prospects for the future.
BibTeX
@article{elkurwi2026battle,
title = {{The Battle Against Systemic Sclerosis: A Case Report of a Patient With Scleroderma Renal Crisis.}},
author = {Noor Elkurwi and Zeineb Garmeh and Qabas Elkurwi and Zahra H Abu Jawhar and Malgorzata Wajdlich},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117638},
url = {https://europepmc.org/article/MED/42999723},
note = {CC BY},
}
RIS
TY - JOUR
TI - The Battle Against Systemic Sclerosis: A Case Report of a Patient With Scleroderma Renal Crisis.
AU - Noor Elkurwi
AU - Zeineb Garmeh
AU - Qabas Elkurwi
AU - Zahra H Abu Jawhar
AU - Malgorzata Wajdlich
PY - 2026
DA - 2026/10/08
JO - Cureus
DO - 10.7759/cureus.117638
UR - https://europepmc.org/article/MED/42999723
AB - Systemic scleroderma (SSc) is an uncommon autoimmune disorder that causes excessive fibrosis of the skin and internal organs, especially the lungs, kidneys, and heart. Scleroderma renal crisis (SRC) is a rare and potentially fatal complication of SSc. In recent years, there has been an increasing interest in SSc treatment, but so far, the targeted management approach has been lacking. We report a 44-year-old male patient with overlap syndrome (systemic scleroderma, Sjogren's syndrome, and myositis), who underwent treatment with therapeutic plasma exchange (TPE) and received hemodialysis, angiotensin-converting enzyme inhibitors, glucocorticosteroids, and cyclophosphamide. The patient presented prominent cutaneous scleroderma with sclerodactyly and Raynaud's phenomenon. Despite the initial stabilization of the patient's condition on the multimodal pharmacotherapy combined with TPE, he later died from multi-organ failure. Although TPE performed during the early course of the disease has been reported as a potential adjunctive therapy, its efficacy and long-term benefits remain uncertain. Given the complexity of our patient's presentation, including scleroderma overlap syndrome and advanced, irreversible organ damage, it is difficult to determine whether TPE provided a meaningful clinical benefit.
SN - 2168-8184
ER -